Aphria Inc (NYSE:APHA) Speaks Out On Althea’s Manufacturing License

Aphria Inc (NYSE:APHA) is quite impressed by the recent success of its partner Althea. This business partner is based in Australian and has been struggling to obtain a manufacturing license.

About the license

 Aphria has confirmed today that Althea will be free to conduct its business operations. This partner has been looking forward to obtaining proper licensing so that it can freely engage in its manufacturing activities.

Vic Neufeld, who is the CEO of Aphria, has been closely following the activities of the partners. He is impressed by the landmark step and believes that the Althea shareholders can look forward to a brighter future. One of the things they might witness is the establishment of a top-notch medicinal cannabis operation and even more.

Fegan’s thoughts

The CEO of Althea Josh Fegan said that this was a significant step forward for their business. It provided them with authority to engage in the manufacture of cannabis extracts and tinctures. According to him, they are ready to channel resources to produce products following the stipulations of the permit.

Fegan says that they are quite pleased about their success. He also spoke about their existing license for Medicinal Cannabis. According to him, these are very important documents that will see them revamp their production activities.

Fegan has severally congratulated his team for their contributions towards the increased momentum in growth. He has termed the Manufacture License as a great addition that will see them become very competitive.

He also delved deeper to speak about the patients that have already been approved for the company’s medicinal cannabis products. According to him, the number has already surpassed the already set 100 patient milestone. About 127 patients have been approved so far.

The other way to look at the massive success of this business guru is the referrals being made. Reports indicate that many doctors have been prescribing this company’s wide-ranging products to their patients.

Initially, the number prescribing these products stood at 42.Thta number has now risen to stand at 50, and that was over the last two weeks.

The CEO says that these figures are encouraging, considering that they are just starting. He projects that by the same time next year, they will have hit the 100-mark in terms of patients.

By Steven Russell

Steve covers business and investing in emerging medical marijuana markets. Steve graduated from the university of New Orleans with a degree in Broadcast Journalism. Steve has published several articles in professional journals and magazines. His experience gives readers an inside look at the intersection of his specialties, business and medical marijuana.

Leave a Reply

Your email address will not be published. Required fields are marked *

Aphria Inc (NYSE:APHA) Partly-Owned Australian Subsidiary Althea Gets a Manufacture License from the Australian Authorities Aphria Inc (OTCMKTS:APHQF) Returns Focus On The Canadian Cannabis Market Aphria Inc (OTCMKTS:APHQF) Plotting A Total Take-over Of The Adult-Use Cannabis Market Aphria Inc (OTCMKTS:APHQF) Unveils Global Expansion Plans Through Acquisition Of Latin American And Caribbean Assets Aphria Inc (OTCMKTS:APHQF) Gives A Major Boost To Its Leadership With New Appointments As An Exclusive Agreement Is Struck

Pin It on Pinterest